glp-1 obesity drug news today october 2025 Injectable drugs have transformed treatment – and now they're going oral. The FDA recently approved a pill form of semaglutide (Wegovy) for weight loss and for reducing the risk of glp-1 obesity drug news october

Prostate cells express receptors for these hypothalamic hormones, which can either stimulate hyperplasia or be blocked by antagonists to reduce prostate size and inflammation

In the same FDA drug safety communication, post-marketing cases of urosepsis and pyelonephritis were discussed, leading to the addition of warnings of severe infections to the prescribing information for these products

Age, sex, weight, and medical history change baseline hormones and metabolic rates, and these differences matter when selecting peptide type, dose, and timing

Novel mutation of methylmalonyl-CoA mutase gene in a Thai infant with methylmalonic acidemia (mut0)